Adipotide
CKGGRAKDC-GG-D(KLAKLAK)2 · FTPP
Targeted pro-apoptotic peptide that destroys the blood supply to white adipose tissue, causing rapid fat loss in animal studies.
Half-Life
~2–4 hours
MW
N/A
Amino Acids
N/A
Evidence
Preclinical
Regulatory Status
Research compound only
In Plain English
Hunts down the blood supply to white fat tissue and cuts it off — causing fat cells to die from lack of blood flow. Dramatic fat loss in primate studies but kidney toxicity is a serious concern that has prevented human trials.
Overview
Adipotide (also known as FTPP) is a bispecific peptide that selectively homes to white adipose tissue vasculature and induces apoptosis in those blood vessels, cutting off blood supply to fat deposits. Primate studies showed 11% body weight loss and 27% visceral fat reduction in just 28 days, along with significant improvements in insulin sensitivity. One of the most dramatic fat loss compounds in preclinical research.
Common Formats
- Injectable (subcutaneous)
Storage Notes
Freeze at -20°C. Reconstituted: refrigerate and use within 7 days.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Adipotide.
Related Compounds
Semaglutide
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
AOD-9604
A modified fragment of human growth hormone specifically targeting fat metabolism without the growth-promoting or diabetogenic effects of full GH.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.